Literature DB >> 2208573

Serum kinetics of the anti-cancer agent 4-hydroxyandrostenedione in the rat.

J Khubieh1, G W Aherne, J Chakraborty.   

Abstract

A previously described radioimmunoassay (RIA) method for the measurement of 4-hydroxyandrostenedione (4-OHA) was used to investigate the serum drug levels attained after a single oral dose in male and female rats. Marked variability of serum drug concentrations and their time course were evident in male animals at all dose levels. In the female rat, in contrast, serum 4-OHA showed fewer individual differences, rose more rapidly and was sustained at substantially higher concentrations. In all animals, 4-OHA appeared in the serum within 0.5 h following the oral dose and persisted for at least 48 h. Doubling the dose from 8 mg/kg produced a disproportionately large elevation in serum drug levels, but a further increase to 32 mg/kg did not further increase serum levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208573     DOI: 10.1007/bf02897287

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Aromatase inhibitors and their use in controlling oestrogen-dependent processes.

Authors:  A M Brodie; D A Marsh; J T Wu; H J Brodie
Journal:  J Steroid Biochem       Date:  1979-07       Impact factor: 4.292

2.  Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.

Authors:  M Dowsett; D C Cunningham; R C Stein; S Evans; L Dehennin; A Hedley; R C Coombes
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

3.  Inhibition of the formation of 4-hydroxyandrostenedione glucuronide by valproate.

Authors:  I B Parr; M G Rowlands; J Houghton; M Jarman
Journal:  Biochem Pharmacol       Date:  1988-12-01       Impact factor: 5.858

4.  Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer.

Authors:  D Cunningham; T J Powles; M Dowsett; G Hutchison; A M Brodie; H T Ford; J C Gazet; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

Authors:  M Dowsett; P E Goss; T J Powles; G Hutchinson; A M Brodie; S L Jeffcoate; R C Coombes
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

6.  Antibodies to 4-hydroxyandrostenedione--a new anti-breast cancer agent suitable for use in a radioimmunoassay.

Authors:  J Khubieh; G W Aherne; J Chakraborty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.

Authors:  R C Coombes; P Goss; M Dowsett; J C Gazet; A Brodie
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

8.  Radioimmunoassay of the anti-cancer agent 4-hydroxyandrostenedione in body fluids.

Authors:  J Khubieh; G W Aherne; J Chakraborty
Journal:  J Steroid Biochem       Date:  1990-03       Impact factor: 4.292

9.  Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

Authors:  P E Goss; M Jarman; J R Wilkinson; R C Coombes
Journal:  J Steroid Biochem       Date:  1986-02       Impact factor: 4.292

10.  Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.

Authors:  P E Goss; T J Powles; M Dowsett; G Hutchison; A M Brodie; J C Gazet; R C Coombes
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

  10 in total
  2 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Second generation aromatase inhibitor--4-hydroxyandrostenedione.

Authors:  M Dowsett; R C Coombes
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.